Marimekko reported Q1 results roughly in line with our expectations.
Imint continues to face headwinds in the smartphone market, which witnessed its fifth consecutive qu...
Redeye comments on Zordix/Maximum Entertainments Q1-results which were weaker than expected where th...
AcuCort AB (”AcuCort” eller ”Bolaget”) har erhållit godkännande inom samtliga nordiska länder för Bo...
Redeye slightly ups its forecasts and valuation on the back of a strong Q1 2023 report, which marked...
Frånvaron av nya spellanseringar under år 2022 resulterade i en successivt minskad omsättning sedan ...
Modelon remains steadfast in its efforts to enhance the capabilities for cloud scaling in its produc...
Redeye comments on Better Collective’s Q1-results which came in stronger than expected as the compan...
Redeye updates its view on M.O.B.A. Network ahead of its Q1 2023 report due on May 30, 2023.
Redeye updates its estimates following Sozap’s Q1 report.
Redeye states that the Q1 report was solid, but not great.
Redeye retains its positive view on Lagercrantz following a solid Q4 report with 9% organic growth a...
Decent Q1: ARR in line with ABGSCe, adj. EBITDA weaker '23e-'25e ARR unchanged; 1-7% EBITDA cut on h...
Strong backlog allows focus on quality improvements Hands-on focus on Greenland as guidance depends ...
IRLAB and MSRD sign agreement to evaluate IRL757 & IRL942 Successful evaluation may lead to collabor...
Redeye is positively surprised by the evaluation agreement with MSRD, a part of the Otsuka pharmaceu...
Tendo redovisade ingen nettoomsättning och ökad rörelseförlust i det första kvartalet.
Yesterday, on May 15, Sleep Cycle announced that it intends to launch cost-efficiency measures to “i...
Redeye ser positivt på nattens besked att Kanadas läkemedelsmyndighet, Health Canada, har påbörjat s...
Svag utveckling i techsektorn pressar omsättning och lönsamhet Omsättningen i kvartalet uppgick till...
